Making the right diagnosis when radiologic evidence is misleading.
The approval is based on results from the ECHELON-1 trial in previously untreated patients with stage III or IV classical Hodgkin lymphoma.
MM risk rose almost 30% for every 5 kg/m2 increase in young adult BMI.
The analysis identifies relapse-free interval as a prognostic factor.
United States is on the high side for all four subtypes of the disease.
The findings add to a growing body of evidence showing that BTK inhibition disrupts the tumor microenvironment.
Be on the lookout for cancer-specific stress when treating chronic lymphocytic leukemia.
A panel discussion of the challenges and standards of care for managing patients with multiple myeloma.
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
Clinicians reveal the importance of screening for an underlying impaired immune response when patients present with rare symptoms.